S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.26
-0.01 (-3.75%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.26
$0.27
50-Day Range
$0.23
$0.30
52-Week Range
$0.21
$1.32
Volume
2.67 million shs
Average Volume
532,829 shs
Market Capitalization
$32.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
873.9% Upside
$2.50 Price Target
Short Interest
Healthy
2.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.81mentions of Corbus Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$13,663 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.24) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

205th out of 1,135 stocks

Pharmaceutical Preparations Industry

89th out of 557 stocks

CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Stock Down 2.9 %

CRBP Stock traded down $0.01 during midday trading on Friday, hitting $0.26. The stock had a trading volume of 2,667,527 shares, compared to its average volume of 532,829. The firm has a market cap of $32.16 million, a price-to-earnings ratio of -0.89 and a beta of 1.94. The business has a 50-day moving average of $0.27 and a two-hundred day moving average of $0.34. Corbus Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $1.32. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.81 and a quick ratio of 5.85.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. As a group, equities research analysts forecast that Corbus Pharmaceuticals will post -0.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Corbus Pharmaceuticals in a research note on Friday. They set a "hold" rating on the stock.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals: Q4 Earnings Insights
CRBP Jan 2023 2.500 call
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/12/2021
Today
8/13/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+873.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-45,640,000.00
Pretax Margin
-36,209.27%

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$0.39 per share

Miscellaneous

Free Float
114,996,000
Market Cap
$32.16 million
Optionable
Optionable
Beta
1.94

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 47)
    CEO & Director
    Comp: $846.92k
  • Mr. Sean F. Moran CPA (Age 64)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $542k
  • Mr. Craig Stuart Millian M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $542k
  • Dr. Rachael Brake Ph.D. (Age 50)
    Chief Scientific Officer
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR
  • Scott Constantine
    Sr. Director & Head of Clinical Operations













CRBP Stock - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRBP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price targets for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 873.9% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2022?

Corbus Pharmaceuticals' stock was trading at $0.6157 at the beginning of the year. Since then, CRBP shares have decreased by 58.3% and is now trading at $0.2567.
View the best growth stocks for 2022 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.10. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (3.22%), Renaissance Technologies LLC (1.30%), Ikarian Capital LLC (0.69%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.26.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $32.16 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.